- Home
- JYNT vs STTK Comparison
JYNT vs STTK Comparison
Compare JYNT & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JYNT
- STTK
- Stock Information
- Founded
- JYNT 2010
- STTK 2016
- Country
- JYNT United States
- STTK United States
- Employees
- JYNT N/A
- STTK N/A
- Industry
- JYNT Multi-Sector Companies
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- JYNT Miscellaneous
- STTK Health Care
- Exchange
- JYNT Nasdaq
- STTK Nasdaq
- Market Cap
- JYNT 170.3M
- STTK 83.8M
- IPO Year
- JYNT 2014
- STTK 2020
- Fundamental
- Price
- JYNT $10.19
- STTK $2.23
- Analyst Decision
- JYNT Strong Buy
- STTK Hold
- Analyst Count
- JYNT 3
- STTK 6
- Target Price
- JYNT $16.33
- STTK $2.67
- AVG Volume (30 Days)
- JYNT 82.6K
- STTK 1.6M
- Earning Date
- JYNT 11-06-2025
- STTK 11-13-2025
- Dividend Yield
- JYNT N/A
- STTK N/A
- EPS Growth
- JYNT N/A
- STTK N/A
- EPS
- JYNT N/A
- STTK N/A
- Revenue
- JYNT $53,449,713.00
- STTK $2,997,000.00
- Revenue This Year
- JYNT $8.06
- STTK N/A
- Revenue Next Year
- JYNT $11.18
- STTK N/A
- P/E Ratio
- JYNT N/A
- STTK N/A
- Revenue Growth
- JYNT 277.36
- STTK N/A
- 52 Week Low
- JYNT $9.58
- STTK $0.69
- 52 Week High
- JYNT $13.47
- STTK $3.95
- Technical
- Relative Strength Index (RSI)
- JYNT 39.38
- STTK 70.15
- Support Level
- JYNT $9.85
- STTK $1.68
- Resistance Level
- JYNT $10.74
- STTK $2.01
- Average True Range (ATR)
- JYNT 0.21
- STTK 0.26
- MACD
- JYNT -0.03
- STTK 0.06
- Stochastic Oscillator
- JYNT 37.36
- STTK 99.61
About JYNT The Joint Corp.
The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The Company has one operating business segment; The Franchise Operations segment which is comprised of the operating activities of the franchise business unit. The Franchise Operations segment derives revenue from customers by providing access to the Company's franchise license, which represents symbolic intellectual property.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.